Loading…
Employees: 1,477
Size OrbusNeich Medical (6929.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $389M, the 826th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$3.70 on 6 Nov 2026.
Performance Over six months the shares fell 3.1%, against -21.4% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 16.2% over the last twelve months (peer median +12.4%); the operating margin is 23.0% (peer median 8.0%).
Valuation It trades at 8.3× forward earnings against a peer median of 25.9× (cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -18% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -34 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.1 points above its cost of capital (6.3% WACC).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.53B | HK$1.41B | HK$1.28B | HK$1.20B | HK$1.07B |
| Revenue growth | — | +10% | +6% | +12% | — |
| Gross profit | HK$1.05B | HK$936M | HK$875M | HK$821M | HK$711M |
| EBITDA | HK$407M | HK$350M | HK$310M | HK$324M | HK$258M |
| Net income | HK$341M | HK$327M | HK$310M | HK$353M | HK$145M |
| Free cash flow | HK$193M | HK$106M | HK$122M | HK$168M | HK$165M |
| Capital expenditure | HK$199M | HK$143M | HK$87.9M | HK$58.6M | HK$26.1M |
| Total debt | n/a | HK$30.5M | HK$32.6M | HK$58.3M | HK$31.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6929.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.3% | -15.1% | 4th highest of 21 |
| 6-month return | -3.1% | -21.4% | 5th highest of 19 |
| Distance from 52-week high | -24.0% | -42.3% | 4th highest of 21 |
| Revenue growth (TTM) | +16.2% | +12.4% | 9th highest of 20 |
| Operating margin | 23.0% | 8.0% | 4th highest of 20 |
| Forward P/E | 8.3× | 25.9× | cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -18.5% | 0.1% | least demanding of 14 |
| Growth delivered (Del g) | +15.4% | +3.8% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -33.9 pp | +3.5 pp | 3rd least demanding of 14 |
| ROIC minus cost of capital | +10.1 pp | +4.4 pp | 6th highest of 18 |
| EV / EBITDA | 3.8× | 10.7× | cheapest of 9 |
| Net debt / EBITDA | -3.7× | -3.0× | 4th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| OrbusNeich Medical 6929.HK | Hong Kong | $389M | -3% | +16% | 23% | 8.3× | -18.5% | +15.4% |
| Clarity Pharmaceuticals CU6.AX | Australia | $386M | -48% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Medlander Medical Technology 688273.SS | China | $385M | -44% | -12% | 8% | 20.0× | 39.0% | +5.2% |
| Taidoc Technology 4736.TW | Taiwan | $395M | 0% | -6% | 18% | n/a | -8.0% | -6.6% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $380M | -23% | -8% | 17% | 38.5× | 20.0% | +4.4% |
| InBody 041830.KS | South Korea | $378M | +43% | +21% | 19% | 11.4× | -7.6% | +16.9% |
| Jiangsu Apon Medical Technology 300753.SZ | China | $376M | -27% | -15% | -10% | 994.0× | 22.4% | -5.1% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | n/a | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $406M | -13% | +7% | 11% | 27.5× | -2.5% | -6.0% |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $407M | -20% | +46% | 8% | n/a | n/a | n/a |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $407M | -14% | +3% | -45% | n/a | n/a | n/a |
| Cerus CERS | United States | $408M | -23% | +14% | -12% | n/a | n/a | n/a |
| Beijing Succeeder Technology 688338.SS | China | $408M | -15% | -4% | 31% | 18.4× | 9.8% | +3.4% |
| SEERS 458870.KS | South Korea | $409M | -70% | +425% | 43% | 10.1× | -9.1% | +247.0% |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | n/a | -13.2% | +36.8% |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $412M | n/a | +19% | 3% | n/a | 23.3% | +18.1% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | n/a | -12.7% | -1.3% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $417M | +3% | +12% | 6% | 40.9× | 55.5% | +3.8% |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 25.9× | 0.1% | -0.7% |
| YD Bio YDES | United States | $423M | -58% | +17% | -883% | n/a | n/a | n/a |
| SS Innovations International SSII | United States | $423M | -45% | +90% | -16% | n/a | n/a | n/a |